All In Biotech

Drug Trial Radar · NCT03385655

Prostate Cancer Biomarker Enrichment and Treatment Selection

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Last checked: Nov 20, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

200

Actual

Start

Aug 1, 2018

Primary completion

Oct 7, 2024

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
Canadian Cancer Clinical Trials Network; BC Cancer Foundation
First posted
Dec 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.

Conditions

  • Prostate Cancer

Interventions

  • AdavosertibDrug

    250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1

  • SavolitinibDrug

    600mg once daily, orally.

  • DarolutamideDrug

    600mg twice daily, orally.

  • CFI-400945Drug

    Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.

  • IpatasertibDrug

    400mg daily 3 weeks on, 1 week off

  • Durvalumab and TremelimumabDrug

    Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1

  • CarboplatinDrug

    AUC 5 IV 60min Day 1 q 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical benefit rate defined as proportion of patients who had PSA decline ≥ 50%, complete or partial objective response, or Stable disease for ≥ 12 weeks.Time frame: 2 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • CHUM-Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada

  • The Jewish General Hospital

    Montreal, Quebec, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.